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Nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are multidisciplinary liver diseases that often
accompany type 2 diabetes or metabolic syndrome, which are characterized by insulin resistance. Therefore, eﬀective treatment
of type 2 diabetes and metabolic syndrome should target not only the cardiometabolic abnormalities, but also the associated liver
disorders. In the last decade, it has been shown that metformin, thiazolidinediones, vitamin E, ezetimibe, n-3 polyunsaturated fatty
acids, renin-angiotensin system (RAS) blockers, and antiobesity drugs may improve hepatic pathophysiological disorders as well
as clinical parameters. Accordingly, insulin sensitizers, antioxidative agents, Niemann-Pick C1-like 1 (NPC1L1) inhibitors, RAS
blockers, and drugs that target the central nervous system may represent candidate pharmacotherapies for NAFLD and possibly
NASH. However, the eﬃcacy, safety, and tolerability of long-term treatment (potentially for many years) with these drugs have not
been fully established. Furthermore, clinical trials have not comprehensively examined the eﬃcacy of lipid-lowering drugs (i.e.,
statins, fibrates, and NPC1L1 inhibitors) for the treatment of NAFLD. Although clinical evidence for RAS blockers and incretin-
based agents (GLP-1 analogs and dipeptidyl peptidase-4 inhibitors) is also lacking, these agents are promising in terms of their
insulin-sensitizing and anti-inflammatory eﬀects without causing weight gain.
1. Introduction
Over the past two decades, the prevalence of metabolic
abnormalities such as type 2 diabetes and metabolic syn-
drome (MetS) has been increasing worldwide together with
the escalating obesity pandemic [1–3]. Abdominal obesity,
in particular, substantially increases the risk of develop-
ing type 2 diabetes, MetS, and fatty liver. According to
the American Association for the Study of Liver Diseases
(AASLD), fatty liver in the absence of a chronic increase in
alcohol intake (i.e., alcohol intake is <20 g ethanol/day) is
referred to as nonalcoholic fatty liver disease (NAFLD) [4].
According to the AASLD’s practice guidelines for NAFLD
[5], NAFLD is histologically subdivided into nonalcoholic
fatty liver (NAFL) and a more severe condition, nonalcoholic
steatohepatitis (NASH), which sometimes advances over
several decades to life-threatening hepatic cirrhosis and
hepatocellular carcinoma. The prevalence of NAFLD, as
detected by ultrasound, is up to 30–46% in developed
countries and nearly 10% in developing nations, making
NAFLD the most common liver disorder worldwide [5, 6].
Lifestyle interventions such as diet and moderate exer-
cise, which lead to weight loss, are fundamental for the
treatment of NAFLD. Paradoxically, NAFLD has also been
reported in nonobese people [7–9]. In India, individuals
with a normal BMI (18.5–24.9 kg/m2) have a 2-fold higher
risk of developing NAFLD compared with those with a
BMI of <18.5 kg/m2 [10]. Therefore, NAFLD is expected
to become a major burden in Asian countries where the
prevalence of obesity is less than that in Western countries
[10, 11]. Notably, NAFLD appears to be an early predictor
of metabolic disorders, particularly among normal-weight
individuals [7]. This is because NAFLD may be more
tightly associated with insulin resistance and with markers
of oxidative stress and endothelial dysfunction than with the
Adult Treatment Panel III criteria for MetS in nonobese,
nondiabetic subjects [8]. Therefore, although obese peo-
ple are predisposed to develop NAFLD, normal weight
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and overweight people may, through the development of
insulin resistance, also show the pathogenic characteristics of
NAFLD.
The clinical relevance of NAFLD is still poorly under-
stood because some investigators [12–15], but not all [16,
17], have shown that NAFLD is associated with higher overall
mortality and cardiovascular disease. Since NAFLD is closely
associated with obesity, diabetes, and MetS, it is unknown
whether the relationship between NAFLD and all-cause
mortality and cardiovascular death, if any, is independent of
cardiometabolic risk factors (Figure 1) such asMetS and type
2 diabetes.
Taken together, NAFLD and NASH are multidisciplinary
liver diseases that require interventions targeting the car-
diometabolic and liver disorders for the eﬀective treatment
of patients with these diseases. Therefore, it is likely that
mild NAFLD will require predominantly cardiometabolic
pharmacotherapies, whereas moderate to severe NAFLD
and NASH will require pharmacotherapies targeting the
hepatic disorders. However, since many of the candidate
drugs are likely to have broad therapeutic eﬀects targeting
multiple aspects of these diseases, distinct classifications are
unavailable.
2. Liver-Specific Pathogenic Characteristics of
NAFLD and NASH
Ectopic fat deposition in organs other than fat tissue,
such as the liver and skeletal muscle, reflects severe energy
overaccumulation or disturbed fat distribution. However,
hepatocytes can, under physiological conditions, store small
amounts of triglyceride in a transient manner [18].
Low physical activity as a result of a sedentary state, other
unfavorable lifestyle behaviors (e.g., diet and habitual smok-
ing), and sympathetic overdrive as a result of physical/mental
stress may lead to insulin resistance independently of obesity.
In turn, insulin resistance suppresses the influx of glucose
and free fatty acids (FFAs) into adipose tissue, increasing FFA
influx into the liver.
The pathogenic characteristics described above are often
observed inmetabolically obese young women with a normal
body weight [19, 20]. Stefan et al. [21] proposed that reduced
ectopic fat in the liver may be more important than reduced
visceral fat for the discrimination of benign obesity, in
other words metabolically normal obesity with good insulin
sensitivity.
Ectopic fat deposition in the livermay be an initial feature
of peripheral insulin resistance, particularly in adipose tissue,
which predominantly accumulates surplus energy as fat.
For many years, it was thought that simple steatosis (i.e.,
fatty liver) remains benign throughout life. However, studies
published in the last two decades have shown that such
conditions, without appropriate treatment or intervention,
provoke other events, including oxidative stress, inflamma-
tion, and fibrosis. These events lead to the degeneration and
impaired functioning of liver tissue and ultimately result
in NASH. Unfortunately, similar to other cardiometabolic
diseases, most people with asymptomatic NAFLD remain
untreated until the results of blood test or imaging studies
indicate the presence of NAFLD. Serum hepatic enzymes,
particularly alanine aminotransferase (ALT), are often ele-
vated beyond the normal range [22–24]. However, they may
remain within the normal ranges [23, 25] and may be over-
looked until abdominal ultrasound, computed tomography,
or magnetic resonance imaging are performed. In clinical
practice, people with hypertrophic abdominal fat cells often
develop NAFLD at a later date. This phenomenon may be
caused by direct influx, via the portal vein, of long-chain
FFAs, glycerol, and proinflammatory cytokines (e.g., tumor
necrosis factor [TNF], interleukin [IL]-6, and IL-1) from the
visceral and upper body fat depots, which exhibit insulin
resistance and activation of hormone-sensitive lipase and
adipose tissue triacylglycerol lipase [26–28].
FFAs derived from the lipolysis of visceral and sub-
cutaneous fat account for approximately 60% of the total
hepatic FFA content [29]. Besides increased FFA influx,
hyperinsulinemia increases hepatic lipogenesis by activating
sterol regulatory element binding protein 1c (SREBP-1c),
a key regulator of lipogenic gene expression. Similarly,
hyperglycemia caused by inadequate insulin action results
in the activation of carbohydrate response element binding
protein, which activates L-type pyruvate kinase and lipogenic
genes in hepatocytes [30].
Nevertheless, it seems unexpected that hepatic lipogene-
sis is not attenuated by decreased insulin sensitivity or insulin
resistance. Recent studies have suggested that SREBP-1c and
lipogenesis are activated secondary to enhanced endoplasmic
reticulum (ER) stress. ER stress activates the cleavage of
SREBP-1c independently of insulin, which may explain the
paradoxical stimulation of lipogenesis in insulin-resistant
liver [31]. Consistently, reducing ER stress in obese animals
decreases SREBP-1c activation and lipogenesis, and improves
hepatic steatosis and insulin sensitivity [32]. Moreover,
ER stress in response to increased hepatic lipid content
attenuates triglyceride secretion by limiting apolipoprotein
B secretion [33], thus increasing hepatic triglyceride accu-
mulation. Alternatively, reduced mitochondrial β-oxidation,
following inhibition of carnitine palmitoyl transferase-1
(CPT-1), may contribute to enhanced fatty acid synthesis
[34].
Several animal studies have also demonstrated a rela-
tionship between decreased microsomal triglyceride transfer
protein (MTP) expression and steatosis [35]. For example,
patients with NASHwere reported to show reduced very low-
density lipoprotein (VLDL) synthesis and impaired hepatic
MTP mRNA expression, which was likely due to single
nucleotide polymorphisms of the MTP gene [36].
3. Pharmacotherapeutic Candidates
for Multidisciplinary Treatment of
NAFLD and NASH
In terms of preventing liver damage, the priority for
pharmacotherapy of NAFLD is to prevent transformation
of NAFLD into NASH and to improve the pathophysiology
[5]. Therefore, in theory, antioxidative, antiinflammatory,
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Figure 1: Therapeutic options and their main eﬀects on NAFLD and NASH.
and antifibrotic agents may constitute first-line treatments
for NAFLD. At the same time, treatments should also be
initiated to target the cardiometabolic abnormalities and
obesity. The potential pharmacotherapies for NAFLD and
NASH are listed in Table 1. The order of the drugs is mostly
based on the recommendation for use [4–6].
3.1. Metformin. Metformin (biguanide) is an insulin-
sensitizer that is considered to be the first-line treatment
of type 2 diabetes because it has relatively few side eﬀects
and is inexpensive. Besides reducing hepatic glucose output,
metformin also activates AMP kinase, which inhibits the
production of glucose, cholesterol, and triglycerides, and
stimulates fatty acid oxidation [37].
Nevertheless, the outcomes of clinical trials in NAFLD
are conflicting [38, 39]. Metformin was more eﬀective than
dietary treatment alone in normalizing several metabolic
parameters [40]. Metformin was also better than a prescrip-
tive diet or vitamin E intake for the treatment of NAFLD in
patients receiving nutritional counseling [41]. In a clinical
study, serum ALT levels were consistently lower in patients
treated with metformin compared with those treated with
placebo [42]. The eﬀects of metformin in that study were
considered to be mediated by weight loss [42].
However, another study showed that metformin only
transiently improved hepatic parameters [43]. Moreover, 6
months of treatment with metformin was no better than
placebo in terms of improving liver histology in patients
with NAFLD [44]. Further well-designed studies are needed
to elucidate the significance of metformin treatment for
NAFLD.
3.2. Thiazolidinediones. A number of clinical trials, includ-
ing randomized controlled trials, have shown that thia-
zolidinediones (peroxisome proliferator activated receptor
[PPAR]-γ agonists) improve liver enzyme levels and liver
histology in patients with NAFLD and NASH [39, 45].
PPARγ, which belongs to the nuclear hormone receptor
family, is predominantly expressed in adipose tissues and
plays a key role in adipogenesis and glucose homeostasis
[46]. Since PPARγ is also expressed in cardiovascular tissues,
such as vascular endothelial cells, smooth muscle cells,
macrophages, and cardiomyocytes, altered PPARγ activity
may be involved in the etiology of cardiovascular diseases,
particularly atherosclerosis [47].
It has been shown that treatment with pioglitazone for
1-2 years improves the overall pathogenic characteristics
of NAFLD and NASH [48–50], suggesting that PPARγ
agonists may improve the pathophysiology of the liver as
well as clinical factors in patients with NAFLD and NASH.
PPARγ regulates several key activities, including adipocyte
diﬀerentiation and fibroblast diﬀerentiation into mature
adipocyte types [51, 52]. Therefore, the improvements in
NAFLD may be due to improvements in the visceral tissue
and upper subcutaneous fat, as thiazolidinediones redirect
fat accumulation from the liver ormuscle into adipose tissues
and confine it in adipose tissue at the expense of adipose cell
expansion [53], which unfortunately leads to weight gain.
Thiazolidinediones also activate AMP-activated protein
kinase and inhibit lipolysis, at least in part by inhibiting the
translocation of hormone-sensitive lipase to lipid droplets
[54]. Mayerson et al. [55] showed that treatment with rosigli-
tazone significantly reduced hepatic triglyceride content and
suppresses adipocyte lipolysis. In this way, rosiglitazone
increased intramyocellular fat storage as triglycerides, which
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Table 1: List of drugs and agents as candidates for the treatment of
NAFLD.
Insulin sensitizers
Metformin (Biguanide)
Thiazolidines (Pioglitazone, Rosiglitazone)
Antioxidants
Vitamin E
Vitamin C
Polyphenols (Resveratrol, etc.)
Hepatocyte-protective agents
Ursodeoxycholic acid
n-3 polyunsaturated fatty acids (EPA and DHA)
Antidyslipidemia
Statins
Fibrates
NPC1L1 inhibitors (ezetimibe)
RAS blockers
Angiotensin II receptor blockers
Angiotensin-converting enzyme inhibitors
Antialdosterone (spironolactone and eplerenone)
Renin inhibitor (aliskiren)
Incretin-related agents
GLP-1 agonists/analogs (exenatide and liraglutide)
DPP-4 inhibitors (sitagliptin and vildagliptin)
Antiobesity drugs
Orlistat
Sibutramine
Mazindol
was accompanied by improved muscle insulin sensitivity.
This suggests that intramyocellular fat alone does not
necessarily reflect insulin resistance.
However, this apparent improvement in insulin resis-
tance often results in adverse outcomes, such as an increase
in the number of adipose cells through enhanced diﬀer-
entiation, eventually leading to weight gain and systematic
edema [39, 50]. These events increase the heart’s workload
and aggravate latent heart failure. Consequently, long-term
treatment with thiazolidinediones may be poorly tolerated
in some people with diabetes because of their adverse
eﬀects, although pioglitazone has fewer side eﬀects than
rosiglitazone [56, 57] (troglitazone was excluded from the
market because of hepatic toxicity). Some adverse eﬀects
of thiazolidinediones, particularly weight gain and edema,
could be prevented when administered in low dosages.
Indeed, even low-dose pioglitazone (15mg/day) improved
liver enzymes without overt adverse eﬀects in a study of 12
patients with biopsy-confirmed NASH [58].
3.3. Vitamin E as an Antioxidative Agent. Some intervention
studies in patients with NAFLD have shown that vitamin E, a
lipophilic antioxidant, may improve some of the pathogenic
characteristics of NAFLD. Vitamin E exerts its antioxidative
eﬀects by reducing lipid peroxidation, preventing free radical
reactions, and stabilizing cellular phospholipid membranes
[59]. Vitamin E also inhibits hepatic transforming growth
factor-β1 expression, attenuates cytokine stimulation of
stellate cells, and protects against hepatic fibrosis [60],
suggesting that vitamin E is more beneficial for NASH rather
than NAFLD.
Nevertheless, clinical trials performed to date have
yielded conflicting results. Some studies, most of them
involving small numbers of patients, showed positive out-
comes in terms of the treatment of NAFLD [41, 48, 61,
62]. However, other studies showed negative results or no
significant improvement with vitamin E compared with
placebo or lifestyle interventions, suggesting that vitamin
E alone is insuﬃcient to treat NAFLD [38, 63]. Lavine et
al. [38] reported that vitamin E and metformin were not
superior to placebo in terms of sustained reductions in ALT
levels in children with NAFLD. It was also reported that
simple lifestyle interventions (i.e., diet and physical exercise)
in children with NAFLD can significantly improve liver
function, glucose metabolism, and lipid levels beyond those
achieved with antioxidant therapy (600 IU/day vitamin E
plus 500mg/day vitamin C) [63]. Several studies have shown
that high-dose vitamin E supplementation may be harmful
in some patients because of unexpected adverse outcomes,
such as increased cardiovascular disease mortality [64, 65],
although other studies found no such risk [66, 67].
Among nondiabetic patients with biopsy-confirmed
NASH, current recommendations advocate the administra-
tion of 800 IU/day vitamin E [5], as this dose may reduce
serum ALT levels and improve steatosis, inflammation, and
hepatocyte ballooning.
3.4. Ursodeoxycholic Acid (UDCA). UDCA is a cytoprotec-
tive antiinflammatory agent that is widely used to treat liver
diseases, as well as gallstones. Long-term clinical studies
have revealed that UDCA safely and eﬀectively improves
hepatic enzyme levels, serum fibrosis markers, and selected
metabolic parameters [68]. Oral administration of taurine-
conjugated UDCA decreased hepatic steatosis in ob/ob mice
by cooperatively regulating multiple metabolic pathways,
including reduced expression of genes that regulate de novo
lipogenesis [69]. Overall, however, there were no significant
diﬀerences between UDCA and placebo in several clinical
trials [70].
3.5. Long-Chain n-3 Polyunsaturated Fatty Acids (PUFAs).
n-3 PUFAs are mainly consumed in the form of marine
oils from fatty fish or other seafood. Fish oil contains both
docosahexaenoic acid (DHA, C22:6 n-3) and eicosapen-
taenoic acid (EPA, C20:5 n-3). n-3 PUFA consumption
lowers plasma triglycerides and blood pressure and may
reduce inflammation and improve vascular function [71].
These eﬀects occur because n-3 PUFAs are natural ligands
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for several nuclear receptors and transcription factors that
regulate gene expression in various tissues [72]. Considering
these properties of n-3 PUFAs, several clinical trials have
investigated the potential eﬀects of fish oil or n-3 PUFA
consumption on the outcomes of cardiovascular disease.
Meta-analyses of these studies have shown that fish oil and
n-3 PUFA consumption, but not α-linolenic acid, reduce the
risk of cardiovascular events and the risk of coronary heart
disease-related mortality [71, 73].
Regarding NAFLD, dietary supplementation with long-
chain n-3 PUFAs appears to safely reduce nutritional hepatic
steatosis in adults [74]. Araya et al. [75] reported that
the levels of n-3 PUFAs were decreased while the n-6/n-3
fatty acid ratio was increased in NAFLD patients compared
with controls, probably because of defective desaturation
of PUFA by inadequate intake of their precursors and
increased peroxidation of PUFA. Petit et al. [76] reported
that increased erythrocyte n-3 and n-6 PUFA levels are
significantly associated with a lower prevalence of steatosis in
patients with type 2 diabetes. In addition, the dietary records
of middle-aged healthy Japanese men revealed that dietary
EPA and EPA + DHA may help to prevent NAFLD [77].
Furthermore, Sato et al. [78] reported that the antiobesity
eﬀects of EPA in high-fat/high-sucrose-induced obese mice
were associated with the suppression of hepatic lipogenesis
and steatosis.
Enjoji and Nakamuta [79] proposed that excess choles-
terol intake appears to be one of the main factors asso-
ciated with NAFLD, particularly in nonobese subjects,
because excess cholesterol consumption stimulates the liver X
receptor-α–SREBP-1c pathway and enhances fatty acid syn-
thesis. Indeed, it was reported that low-dose (2.0% of total
energy) fish oil diets improve hepatic lipid accumulation
in mice fed a high-cholesterol diet [80]. However, studies
examining the eﬀects of EPA/fish oil on dietary cholesterol-
induced NAFLD in humans are still lacking.
3.6. Statins. Statins (3-hydroxy-3-methyglutaryl-coenzyme
A reductase inhibitors) are used worldwide to treat lipid
disorders, particularly elevated low-density lipoprotein-
cholesterol (LDL-C) and substantially reduce cardiovascular
events and mortality. Statins also have pleiotropic eﬀects,
including antiinflammatory actions [81], as they greatly
reduce the levels of proinflammatory cytokines, such as C-
reactive protein (CRP) and TNF.
Although statins are putatively associated with some
adverse events, including elevated hepatic enzymes and
liver dysfunction, an elevated serum ALT level at baseline
attributable to NAFLD is unlikely to increase the risk
of statin-associated elevations in ALT [82]. Similarly, an
elevated baseline serum ALT was not associated with an
increased risk of hepatotoxicity in patients treated with
lovastatin [83].
In clinical studies, simvastatin and atorvastatin [84–86]
were associated with a reduction in hepatic steatosis and may
inhibit the progression to NASH. Four years of treatment
with atorvastatin (20mg) combined with vitamins C and E
reduced hepatic steatosis by 71% in people with NAFLD at
baseline [87]. Taken together with a previous report showing
that excess cholesterol consumption may accelerate NAFLD
[79], statins may be promising candidates for the treatment
of NAFLD. Additionally, some statins improved surrogate
markers of hepatic steatosis, such as serum glyceraldehyde-
derived advanced glycation end-products [88].
On the other hand, considering that statins are associated
with worsening of glucose metabolism [89, 90] and that
multifactorial medications, such as antihypertensive and
antidiabetic drugs, were used in most of the previous
studies of statin therapy [91], well-designed, randomized,
placebo-controlled studies are needed to determination the
suitability of statins as monotherapy or combination therapy
for NAFLD.
3.7. Fibrates. PPARα is highly expressed in the liver and
is involved in fatty acid oxidation [92]. Fibrates, PPARα
agonists, increase FFA oxidation in the liver, alter TG
synthesis, and reduce hepatic synthesis of VLDL [93, 94],
and theoretically improve the pathogenic characteristics of
MetS andNAFLD. Unlike the striking outcomes of numerous
clinical trials using statins, the results of several large studies
of fibrates were inconsistent and had varying outcomes,
including the incidence of cardiovascular mortality and
events [95–99]. In all of these studies, treatment with a
fibrate was associated with a large, although nonsignificant,
reduction in cardiovascular events in people with type 2
diabetes or components of the metabolic syndrome.
To date, however, few clinical studies, except for a small
pilot study [100, 101], have examined the eﬀects of fibrates
on the pathophysiology of NAFLD. Fibrates are expected to
ameliorate the pathogenic characteristics of NAFLD because
they reduce the levels of inflammatory biomarkers, such as
CRP and IL-6, and may improve insulin resistance [102–
104], via mechanisms that diﬀer from those of statins.
Fenofibrate is commonly used in clinical practice because
it is generally well tolerated when used as monotherapy
and as combination therapy in a wide range of individuals
[103, 105].
No clinical studies have examined the eﬀects or safety
of a statin in combination with a fibrate compared with
monotherapy for treating NAFLD. However, some benefits
of combination therapy on cardiovascular andmicrovascular
outcomes were observed in specific subgroups of patients,
such as patients with low HDL levels or hypertriglyceridemia
[106].
3.8. Niemann-Pick C1-Like 1 (NPC1L1) Inhibitors. NPC1L1
plays a key role in intestinal cholesterol absorption. Ezetim-
ibe, an NPC1L1 inhibitor, was reported to reduce circulating
LDL-C levels and improve clinical outcomes in patients at
increased risk for cardiovascular events when administered
alone or in combination with a statin [107]. Unlike in
rodents in which NPC1L1 is mainly expressed in the
intestine, NPC1L1 is highly expressed in the liver in humans
[108, 109]. This suggests that hepatic NPC1L1 may facilitate
hepatic cholesterol accumulation and that ezetimibe may be
a potential candidate for NAFLD, especially NAFLD induced
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by a high-cholesterol diet [79]. In clinical trials, albeit on
a small scale, ezetimibe improved biochemical parameters
and hepatic enzyme levels, as well as the histological
abnormalities of NAFLD [110–112].
3.9. Renin-Angiotensin System (RAS) Blockade. The RAS
plays key roles in the regulation of blood pressure and
fluid balance, as well as in the pathogenesis of insulin
resistance and NAFLD [113, 114]. In addition, inhibition
of the RAS may improve the intracellular insulin signaling
pathway, oﬀering better control of adipose tissue prolifera-
tion and adipokine production [115]. The two main classes
of RAS blockers, angiotensin II receptor blockers (ARBs)
and angiotensin-converting enzyme inhibitors (ACEIs), are
eﬃcient drugs that significantly reduce cardiovascular events
and mortality [116–118]. As expected, ARBs and ACEIs
improve insulin resistance and possibly lipid profiles, sug-
gesting that these agents may be suitable treatments for
NAFLD and NASH. Of interest, telmisartan was reported to
be a partial agonist of PPARγ [119, 120], a property that does
not appear to be shared by other ARBs [121]. Nevertheless,
despite many animal studies showing the beneficial eﬀects of
ARBs and ACEIs, clinical studies for NAFLD are still lacking.
Beneficial eﬀects of spironolactone and eplerenone,
aldosterone antagonists, were recently shown in a mouse
model of NAFLD [121–123]. Additionally, spironolactone in
combination with vitamin E was reported to improve insulin
resistance in patients with NAFLD [124]. However, these
eﬀects of aldosterone antagonists have only been shown in
mouse and small-scale clinical studies.
Aliskiren, a direct renin inhibitor used to treat hyper-
tension, provides an organ-protective eﬀect by attenuat-
ing oxidative stress and improving insulin resistance in
mice models [125–127]. Therefore, although aliskiren is a
promising drug in terms of improving insulin resistance and
oxidative stress, again, human studies are lacking.
3.10. Incretin Modulators. Treatment with incretin modula-
tors, glucagon-like peptide-1 (GLP-1) analogs, and dipep-
tidyl peptidase-4 inhibitors reduces weight gain, minimizes
hypoglycemia, decreases inflammation, and is cardioprotec-
tive in preclinical studies [128, 129]. The most common
adverse events are mild gastrointestinal tract symptoms such
as nausea, vomiting, and diarrhea, the incidence and severity
of which generally decreased during continued therapy
[129].
Regarding the beneficial eﬀects of incretin modulators,
weight loss (or weight neutrality) and reduced inflammation
appear to be particularly promising for the treatment of
NAFLD because these eﬀects facilitate improvements in
insulin resistance and metabolic abnormalities. Ding et al.
[130] reported that administration of exendin-4, a GLP-1
receptor agonist, induces the regression of hepatic steatosis
in ob/ob mice by improving insulin sensitivity. GLP-1 appears
to protect hepatocytes from fatty acid-related death by sup-
pressing dysfunctional ER stress responses [131]. In addition,
GLP-1 suppresses hepatic lipogenesis by activating the AMP
kinase pathway and reduces hepatic fat accumulation and
nutrient-induced hepatic proinflammatory responses [132].
Tushuizen et al. [133] reported that 44 weeks of exenatide
therapy decreased liver fat measured by liver spectroscopy
from 15.8% to 4.3% and improved hepatic enzymes in
a patient with type 2 diabetes. Taken together, there are
promising results in animal models and limited human
reports, but clinical studies examining the eﬀects of incretin-
based agents on hepatic steatosis have not been performed.
3.11. Antiobesity Drugs. Theoretically, improving NAFLD
via weight loss is an ideal approach in obese or overweight
people because other complications are simultaneously ame-
liorated. Of several commonly used antiobesity medications
[134], orlistat and sibutramine are available for long-term
prescription [135, 136]. Orlistat inhibits dietary triglyceride
hydrolysis in the gut, occasionally with mild gastrointestinal
symptoms, resulting in a substantial decrease in fat absorp-
tion. Zelber-Sagi et al. [137] showed that orlistat improves
serum ALT levels and steatosis determined by ultrasound
in patients with NAFLD, beyond its weight-lowering eﬀects.
Harrison et al. [138] reported that subjects who lost ≥5% of
their body weight over 9 months experienced improvements
in insulin resistance and steatosis, while subjects who lost
≥9% of their body weight also experienced improvements in
hepatic histology.
Sibutramine, a combined norepinephrine and serotonin
reuptake inhibitor, reduces food intake and body weight.
Both orlistat and sibutramine had beneficial eﬀects on body
weight, lipid profiles, glucose metabolism, and inflammatory
markers in many trials [135, 137]. However, there is still
insuﬃcient safety data regarding the long-term outcomes
of antiobesity therapy. Indeed, sibutramine was reported to
increase blood pressure and heart rate, which may limit its
use in clinical practice [135].
Mazindol, a tetracyclic chemical, has been approved in
several countries, including Japan. However, long-term treat-
ment with mazindol is not currently permitted, although
treatment with mazindol for a few weeks to several months is
allowed in severely obese individuals (e.g., BMI ≥ 35 kg/m2
in Japan). The combination of mazindol and diet therapy
is eﬀective in treating severe obesity [139]. Mazindol exerts
antiobesity eﬀects by inhibiting the appetite and activat-
ing thermogenesis, as well as having antidiabetic eﬀects
[140]. However, clinical studies of mazindol have not been
conducted in patients with NAFLD, partly because of the
restriction for short-term administration.
Rimonabant, a selective cannabinoid-1 (CB1) receptor
blocker, was shown to reduce body weight and improve
cardiovascular risk factors in obese patients by regulating the
energy balance and body composition [141]. Furthermore,
administration of 20mg rimonabant daily in combination
with a hypocaloric diet for 1 year, significantly decreased
body weight and waist circumference [142]. Based on
several trials showing its weight loss benefits, rimonabant
entered the European market for the treatment of obesity
[143]. However, the drug was withdrawn worldwide in
2008-2009 because of the emergence of significant side
eﬀects, particularly psychiatric disorders (e.g., depression
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and anxiety) [143, 144]. The CB1 receptor is expressed not
only in the central nervous system but also in the gas-
trointestinal tract, adipose tissue, and cardiovascular system
[145]. Consistently, animal studies have shown that CB1
receptor antagonists improve glucose homeostasis, insulin
levels, fatty liver, and plasma lipid profiles by blocking
the CB1 receptor in peripheral tissues, including the liver
and visceral fat [146, 147]. Despite these promising eﬀects,
the clinical application of CB1 receptor antagonists will be
restricted until their critical adverse eﬀects on the central
nervous system can be overcome.
3.12. Resveratrol. Polyphenols, ubiquitous dietary compo-
nents that mainly include flavonoids and tannins, are
considered dietary supplements rather than drugs. Several
polyphenols obtained from plants may be promising can-
didate treatments for NAFLD and NASH because they are
eﬀective scavengers of reactive oxygen and reactive nitrogen
species [148].
Of several polyphenols described to date, resveratrol,
a component of several grape species, appears to be par-
ticularly relevant in the context of liver disease [149]. For
example, resveratrol has antiinflammatory eﬀects mediated
through a decrease in proinflammatory cytokines, including
TNF. In a study using an animal model of steatosis,
resveratrol significantly reduced hepatic steatosis and ALT
levels [150]. Resveratrol appeared to reduce liver oxidative
stress by increasing the expression of CPT-1a and acyl-
coenzyme A oxidase. Another study revealed that resveratrol
can also protect the liver from NAFLD by reducing FFA
availability [151]. Resveratrol also decreased the severity of
NAFLD in rats, at least in part, through its antioxidant eﬀects
and by inhibiting TNF [152]. Resveratrol was also reported to
protect the liver from NAFLD by enhancing AMP-activated
protein kinase phosphorylation [153].
3.13. Alcohol Intake. Habitual alcohol intake, even light con-
sumption, interferes with the development and progression
of critical diseases. Intriguingly, light to moderate alcohol
consumption is often associated with a low prevalence of
fatty liver. Clinical studies have suggested that light or mod-
erate (<10–20 g ethanol/day) alcohol intake protects against
NAFLD [154]. Light alcohol consumption (20 g ethanol
on 1–3 days/week or 40–140 g ethanol/week) and mod-
erate alcohol consumption (140–280 g ethanol/week) were
independently associated with a low prevalence of fatty
liver [155, 156], whereas moderate to heavy drinking
(>60 g ethanol/week) was associated with the progression of
hepatic steatosis and fibrosis [157, 158].
The eﬀects of moderate alcohol consumption on liver
enzymes may increase with increasing BMI [159]. In
addition, habitual alcohol consumption generally impairs
fatty acid oxidation and stimulates lipogenesis [160, 161].
However, the specific mechanisms by which alcohol (alone
or in combination with obesity/metabolic abnormalities)
causes liver injury are poorly understood. In clinical studies,
the causality between light to moderate alcohol consumption
and reduced prevalence of fatty liver or NAFLD remains
unknown. Thus, patients with NAFLD should not consume
heavy amounts of alcohol [5, 162]. Additionally, no recom-
mendation can be made regarding even light to moderate
alcohol consumption [5].
4. Conclusion
Since hepatic dysfunction is usually closely associated with
systemic disorders, there are no specific medications that
ameliorate only the pathogenic characteristics of fatty liver
without aﬀecting other organs and tissues. In other words,
drugs used, or expected to be used, in the treatment of
type 2 diabetes, MetS (i.e., hypertension and dyslipidemia),
hypercholesterolemia, and obesity may be candidate drugs
for the treatment of NAFLD and NASH. These agents can be
more eﬀective than monotherapy, although further evidence
from animal and cellular studies, as well as large clinical
trials, is needed to examine this possibility.
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